Alpenglow Biosciences and Incyte Corporation to Present 3D Imaging Research at SID 2025
Alpenglow Biosciences and Incyte Corporation to Present 3D Imaging Research at SID 2025
We are pleased to share that our collaborative research with Incyte Corporation has been accepted for an ePoster presentation at the Society for Investigative Dermatology (SID) 2025 Annual Meeting.
Presentation Title:
"3D imaging elucidates neuroimmune dynamics in atopic dermatitis skin treated with ruxolitinib cream."
Authors:
Angelina Volkova, PhD; Chifei Sun, MSc; Heather Bullins, AAS; Konstantin Popovic, PhD; Shikhar Dhingra, MSc; Nathan Grant, MSc; Caleb Stoltzfus, PhD; Nicholas P. Reder, MD, MPH; Cynthia Timmers, PhD; Susan H. Smith, PhD
Presentation Details:
🔹 Session Title: ePoster Talks (Session 2) – Clinical Research: Interventional Research
🔹 Session Date & Time: May 9, 2025, from 4:45 PM to 5:45 PM
🔹 Room: Sapphire E/F
🔹 Presentation Time: 5:40 PM – 5:45 PM
Led by Incyte Corporation, this research investigates the effects of 1.5% ruxolitinib cream on the neuroimmune landscape in atopic dermatitis (AD) using biopsy samples from the SCRATCH-AD study. Alpenglow Biosciences provided advanced 3D imaging and machine learning-driven analysis, providing a detailed analysis of nerve volume, immune cell distribution, and epidermal remodeling in response to treatment.
Partnering with Incyte on this study underscores the power of cutting-edge 3D imaging in dermatological research applying cutting-edge 3D imaging technology to provide an unprecedented view of spatial relationships within the skin microenvironment.
Using Alpenglow’s proprietary Aurora 3Di light-sheet microscopy and advanced 3D analysis workflows, this study showcases how high-resolution, volumetric imaging can capture entire tissue structures in ways that traditional 2D methods cannot.
By enabling a more comprehensive and unbiased evaluation of cellular organization, nerve-immune interactions, and tissue architecture, 3D imaging offers new opportunities to deepen our understanding of skin diseases and therapeutic responses.
We are honored to support Incyte’s research in advancing treatment options for atopic dermatitis, a chronic and burdensome disease affecting millions worldwide. Through this collaboration, we strive to advance scientific innovation that translates into meaningful clinical impact, ultimately improving the lives of those affected by AD.
We look forward to presenting this exciting work at SID 2025 and engaging with the dermatology community on the impact of 3D imaging in clinical applications.
